Lancaster Resources Inc. has opted to move from quarterly to semi-annual financial reporting under a Canadian pilot program to reduce administrative costs. The company will no longer file interim reports for certain quarters but will continue annual and six-month filings. Following an unsuccessful financing attempt, Lancaster is exploring strategic alternatives including partnerships and asset sales to preserve capital. It also decided to terminate its option on the Lake Cargelligo project to focus resources on higher-priority projects in Quebec. Additionally, the CFO resigned, and the company is reviewing the role amid its strategic review.
Lancaster Resources Inc.'s recent corporate update and shift to semi-annual reporting come with this market snapshot from Pluang's Basic Materials sector. As of Sep 19, 2026 05:11 WIB, out of 34 priced US stocks, 14 rose and 19 fell. Notable movers include LYB at USD 62.03 with a 1-day change of -3.43% and a typical hold time of 84 days, MP at USD 47.84 down 3.12% with a 2-day hold time, and KGC at USD 28.64 up 2.95% with a 52-day hold time and 98% sell order activity.
Janet Kerr, a director at La-Z-Boy, has sold 3,653 shares of the company, generating $116,000 from the transaction. This sale could indicate a personal financial decision or portfolio adjustment, but it may also attract investor attention regarding i...
Shares of TJGC Group Limited jumped nearly 54% after announcing plans to expand into AI hardware, led by new leadership in electronics manufacturing. Forward Industries rose 24% following an updated acquisition proposal for SkyAI, offering a 50% prem...
Anthropic is targeting a November initial public offering (IPO), delayed from an expected October debut, to potentially share strong third-quarter financial results. The company’s revenue surged from $9 billion at the end of 2025 to $65 billion by Ju...
Circle launched its Arc mainnet on September 16, 2026, with a strict policy that stolen USDC funds on the network cannot be recovered through rollbacks. Circle's Chief Product and Technology Officer, Nikhil Chandhok, explained that immutability is a ...
Replimune Group faces a class action lawsuit alleging it misled investors about the efficacy and viability of its lead cancer drug candidate RP1. The FDA rejected Replimune's Biologics License Application (BLA) for RP1 combined with nivolumab due to ...
